Most remarkably, this study provides new data on DENV strains circulating in Africa, where only scarce data

are available. The role of travelers and nonendemic countries as an additional source of epidemiological data on infectious diseases, complementary to the information available from endemic countries, has been demonstrated.7–9 Samples (sera and/or viral culture supernatants) were collected by virology research laboratories of the European Network for Diagnosis of “Imported” Viral Diseases (ENIVD) or travel clinics members of the European Network on Imported Infectious Diseases Surveillance (TropNetEurop) from 2002 to 2008. Seven ENIVD laboratories participated in the study, which are all national reference laboratories. HIF inhibitor review They received samples routinely from a wide range of clinics and hospitals in the countries for dengue confirmation. Within the TropNetEurop a total of five travel selleckchem clinics participated. In these clinics, a suspected dengue case was defined as

a patient with travel history in the previous 15 days to a dengue endemic area, who presented fever plus two of the following symptoms or hematological findings: myalgia, arthralgia, headache, retro-orbital pain, malaise, rash, bleeding tendencies, positive tourniquet test, leucopoenia, or thrombocytopenia. Further details on the clinical presentations of dengue patients included have been published previously.10,11 Confirmation of acute dengue infection in those serum samples received during the study and case classification (primary or secondary infections) were carried out by molecular and serological diagnosis.12 Samples were stored at −80°C until further processing. Viral RNA was obtained using the QIAamp

Viral RNA Minikit (Qiagen, Hilden, Germany). RNA was subjected to a reverse transcriptase-polymerase chain reaction (RT-PCR) (Access One-Step RT-PCR, Abiraterone purchase Promega GmbH, Mannheim, Germany) to amplify a 445, 529, 459, and 460 bp fragment for DENV-1, DENV-2, DENV-3, and DENV-4, respectively, spanning the E/NS1 junction of the DENV genome.13 A multiplex-nested PCR was carried out, using a mix of dengue-specific oligonucleotides (Table 1). Positive samples which showed higher viral loads were also subjected to a specific DENV RT-nested PCR to amplify the complete E gene using specific primers for each DENV serotype (Table 2). The sequences of the E/NS1 fragment were obtained using the forward and the reverse primer-nested PCR mix flanking the amplification product, and the ABI Prism Dye terminator cycle sequencing ready reaction kit (Applied Biosystems, Foster City, CA, USA). A minimum number of four sequences were compiled to gain a consensus sequence. To sequence the complete E gene, different DENV serotype specific primers were used to obtain overlapping sequences (Table S1, Supporting Information). Original sequence data were first analyzed by the CHROMAS software (version 1.